Abstract
The role of brain natriuretic peptide (BNP) as a screening tool for left ventricular systolic dysfunction (LVSD) in primary care remains unclear. We compared the efficacy of BNP with that of a 12 lead electrocardiogram (ECG) as a screening tool for LVSD in the setting of open access echocardiography and found BNP to be more sensitive in excluding LVSD than an ECG. The use of BNP in screening for LVSD resulted in a saving of £10 per patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
